FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023043669> ?p ?o ?g. }

• W2023043669 abstract "In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be intensified by addition of cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR). The radioimmunotherapy with cetuximab is a feasible treatment option showing a favourable toxicity profile. The most frequent side effect of radiotherapy is radiation dermatitis, the most common side effect of treatment with cetuximab is acneiform rash. Incidence and severity of these frequent, often overlapping and sometimes limiting skin reactions, however, are not well explored. A clinical and molecular differentiation between radiogenic skin reactions and skin reactions caused by cetuximab which may correlate with outcome, have never been described before. The HICARE study is a national, multicenter, prospective phase IV study exploring the different types of skin reactions that occur in patients with LASCCHN undergoing radioimmun(chemo)therapy with the EGFR inhibitor cetuximab. 500 patients with LASCCHN will be enrolled in 40 participating sites in Germany. Primary endpoint is the rate of radiation dermatitis NCI CTCAE grade 3 and 4 (v. 4.02). Radioimmunotherapy will be applied according to SmPC, i.e. cetuximab will be administered as loading dose and then weekly during the radiotherapy. Irradiation will be applied as intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy. The HICARE trial is expected to be one of the largest trials ever conducted in head and neck cancer patients. The goal of the HICARE trial is to differentiate skin reactions caused by radiation from those caused by the monoclonal antibody cetuximab, to evaluate the incidence and severity of these skin reactions and to correlate them with outcome parameters. Besides, the translational research program will help to identify and confirm novel peripheral blood based molecular predictors and surrogates for treatment response and resistance. Clinical Trial Identifier, NCT01553032 (clinicaltrials.gov) EudraCT number: 2010-019748-38" @default.
• W2023043669 created "2016-06-24" @default.
• W2023043669 creator A5010170241 @default.
• W2023043669 creator A5031111654 @default.
• W2023043669 creator A5041314787 @default.
• W2023043669 creator A5055006530 @default.
• W2023043669 creator A5060684551 @default.
• W2023043669 creator A5065888107 @default.
• W2023043669 creator A5067776208 @default.
• W2023043669 creator A5075116222 @default.
• W2023043669 date "2013-07-15" @default.
• W2023043669 modified "2023-09-27" @default.
• W2023043669 title "Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial" @default.
• W2023043669 cites W1912423223 @default.
• W2023043669 cites W1923056904 @default.
• W2023043669 cites W1965734230 @default.
• W2023043669 cites W1968151389 @default.
• W2023043669 cites W1976262124 @default.
• W2023043669 cites W1990441347 @default.
• W2023043669 cites W1990967992 @default.
• W2023043669 cites W2002019750 @default.
• W2023043669 cites W2017005150 @default.
• W2023043669 cites W2019607817 @default.
• W2023043669 cites W2023660230 @default.
• W2023043669 cites W2031520822 @default.
• W2023043669 cites W2060763328 @default.
• W2023043669 cites W2064047613 @default.
• W2023043669 cites W2064810566 @default.
• W2023043669 cites W2072608181 @default.
• W2023043669 cites W2110125130 @default.
• W2023043669 cites W2110664940 @default.
• W2023043669 cites W2116869271 @default.
• W2023043669 cites W2117781588 @default.
• W2023043669 cites W2126372889 @default.
• W2023043669 cites W2131971625 @default.
• W2023043669 cites W2133238086 @default.
• W2023043669 cites W2134920919 @default.
• W2023043669 cites W2136871952 @default.
• W2023043669 cites W2139230093 @default.
• W2023043669 cites W2144020201 @default.
• W2023043669 cites W2151730005 @default.
• W2023043669 cites W2155384808 @default.
• W2023043669 cites W2161235601 @default.
• W2023043669 cites W2163186602 @default.
• W2023043669 cites W2163592822 @default.
• W2023043669 cites W2168377135 @default.
• W2023043669 cites W2170971614 @default.
• W2023043669 cites W2316316905 @default.
• W2023043669 cites W23246608 @default.
• W2023043669 cites W4238391111 @default.
• W2023043669 doi "https://doi.org/10.1186/1471-2407-13-345" @default.
• W2023043669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3751099" @default.
• W2023043669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23855804" @default.
• W2023043669 hasPublicationYear "2013" @default.
• W2023043669 type Work @default.
• W2023043669 sameAs 2023043669 @default.
• W2023043669 citedByCount "8" @default.
• W2023043669 countsByYear W20230436692014 @default.
• W2023043669 countsByYear W20230436692015 @default.
• W2023043669 countsByYear W20230436692017 @default.
• W2023043669 countsByYear W20230436692020 @default.
• W2023043669 countsByYear W20230436692021 @default.
• W2023043669 countsByYear W20230436692023 @default.
• W2023043669 crossrefType "journal-article" @default.
• W2023043669 hasAuthorship W2023043669A5010170241 @default.
• W2023043669 hasAuthorship W2023043669A5031111654 @default.
• W2023043669 hasAuthorship W2023043669A5041314787 @default.
• W2023043669 hasAuthorship W2023043669A5055006530 @default.
• W2023043669 hasAuthorship W2023043669A5060684551 @default.
• W2023043669 hasAuthorship W2023043669A5065888107 @default.
• W2023043669 hasAuthorship W2023043669A5067776208 @default.
• W2023043669 hasAuthorship W2023043669A5075116222 @default.
• W2023043669 hasBestOaLocation W20230436691 @default.
• W2023043669 hasConcept C121608353 @default.
• W2023043669 hasConcept C126322002 @default.
• W2023043669 hasConcept C143998085 @default.
• W2023043669 hasConcept C159654299 @default.
• W2023043669 hasConcept C203014093 @default.
• W2023043669 hasConcept C2776146153 @default.
• W2023043669 hasConcept C2776530083 @default.
• W2023043669 hasConcept C2776833033 @default.
• W2023043669 hasConcept C2779998722 @default.
• W2023043669 hasConcept C509974204 @default.
• W2023043669 hasConcept C526805850 @default.
• W2023043669 hasConcept C535046627 @default.
• W2023043669 hasConcept C542903549 @default.
• W2023043669 hasConcept C71924100 @default.
• W2023043669 hasConceptScore W2023043669C121608353 @default.
• W2023043669 hasConceptScore W2023043669C126322002 @default.
• W2023043669 hasConceptScore W2023043669C143998085 @default.
• W2023043669 hasConceptScore W2023043669C159654299 @default.
• W2023043669 hasConceptScore W2023043669C203014093 @default.
• W2023043669 hasConceptScore W2023043669C2776146153 @default.
• W2023043669 hasConceptScore W2023043669C2776530083 @default.
• W2023043669 hasConceptScore W2023043669C2776833033 @default.
• W2023043669 hasConceptScore W2023043669C2779998722 @default.
• W2023043669 hasConceptScore W2023043669C509974204 @default.
• W2023043669 hasConceptScore W2023043669C526805850 @default.
• W2023043669 hasConceptScore W2023043669C535046627 @default.
• W2023043669 hasConceptScore W2023043669C542903549 @default.

• next